Molecular Study of the Maternal-fetal Interface in Preeclampsia.

Launched by CARLOS SIMON FOUNDATION · Jan 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called preeclampsia, which can cause serious health problems for both pregnant women and their babies. The researchers want to find early signs that can help identify women at risk of developing preeclampsia. They will collect small tissue samples from the placenta, called chorionic villi, from pregnant women between 9 and 14 weeks of pregnancy who are already scheduled for a specific test called a chorionic villus biopsy. By looking for certain biological markers in these samples, the study aims to improve early detection of preeclampsia and help prevent its complications.

To participate in this study, women must be over 18 years old, have a single pregnancy, and give their consent to join the trial after being informed about the study. However, women who are pregnant with more than one baby or have certain pregnancy complications will not be eligible. If you choose to participate, you can expect a simple procedure to collect the tissue sample, and your contribution could help improve the care of future pregnant women at risk for preeclampsia.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved.
• • Women over the age of 18 at the time of signing the informed consent form.
• • Pregnant women with a single gestation between weeks 9 and 14 of gestation who will undergo a chorionic villus biopsy according to the centre's usual clinical practice.
• Exclusion Criteria:
• • Women with multiple pregnancy.
• • Non-evolving pregnancies (including delayed abortion/foetal orbit).